Introduction Hypophosphatemic rickets with hypercalciuria is a rare recessively-inherited form of rickets caused by homozygous or compound heterozygous mutations in SLC34A3 that encodes the renal tubular phosphate transporter, NaPi2c. The bone phenotype varies from severe rickets through to no disease. Accurate diagnosis is important as the treatment differs from other forms of rickets.
Introduction
Hereditary hypophosphatemic rickets with hypercalciuria (HHRH; OMIM 241530) is a rare autosomal recessive disorder originally described in a consanguineous kindred in 1985 [1, 2] . In 2006, mutations in the gene SCL34A3 that encodes the renal tubular sodium-phosphate cotransporter NaPi2c were identified as the cause of the disorder in the original kindred and several other families [3, 4] . Individuals who carry compound heterozygous or homozygous loss-offunction mutations in SLC34A3, have urinary phosphate wasting and chronic hypophosphatemia that can lead to hypophosphatemic rickets. Plasma calcitriol levels are usually elevated and cause hypercalciuria -primarily through enhanced intestinal calcium absorption. Hypercalciuria leads in turn to the development of kidney stones and/or nephrocalcinosis. The clinical manifestations in bone are highly variable: some patients have no obvious bone abnormality, while others have rickets that can range from mild to severe. It is uncertain what underlies this variation in phenotype [5] . In this paper we describe a case of unusually severe hypophosphatemic rickets in a boy in whom we identified a novel homozygous mutation in SLC34A by massive parallel sequencing, using a panel directed to hereditary forms of rickets/osteomalacia. We have also reviewed the published literature to examine whether the bone phenotype relates to the nature of the mutations in SLC34A3 or the severity of hypophosphatemia.
Case Report
A 12-year-old boy was referred with complaints of recurrent fractures, bone pain and severe progressive limb deformities. He had a renal stone at the age of 2 and rickets had been diagnosed at the age of 3. At first it had been thought that the rickets was nutritional in origin, but his condition deteriorated despite vitamin D and calcium treatment. Bone pain and deformities caused severe restriction of activity. By the age of 3 he was non-ambulant and unable to attend school. His parents were first cousins, but there was no family history of bone disease.
Physical examination showed short stature, (height 110 cm, 4.5 standard deviations [SD] below the mean of age-matched Indian boys). The sclerae were white. He had classical rachitic deformities including pectus carinatum, Harrison sulcus and rickety rosary, with bowing deformities of the arms and legs (Figure 1) . The long bones were painful to touch.
Skeletal radiographs showed florid rickets with multiple fractures and Looser zones, gross widening of the metaphyses, thin cortices and marked clavicular and long bone deformities
(Figure 2 A-C).
A renal sonogram showed bilateral nephrocalcinosis. Laboratory studies showed a normal blood count, renal function and electrolytes. Biochemical measurements related to mineral metabolism are shown in Table 1 . The plasma calcium was normal but the phosphate was low (4.7 SD below the mean for his age). The alkaline phosphatase was elevated and the serum parathyroid hormone undetectable. Plasma concentrations of calcidiol, calcitriol and FGF23 were within the normal ranges. His 24 hr urinary calcium excretion was elevated. The TmP/GFR was not formally assessed.
Methods

Genetic analysis
The early presentation with rickets that did not respond to vitamin D therapy and parental consanguinity suggested a genetic cause. The patient's phenotype was thought to fit best with HHRH. We investigated this using a massive parallel gene sequencing (MPS) panel directed 
Literature review
We identified publications describing the phenotype of 56 patients from 34 families who had either homozygous mutations or compound heterozygous mutations in SLC34A3. [1] [2] [3] [4] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] .
We compared serum phosphate levels in those reported to have rickets with those reported to have only renal complications. As normal values for serum phosphate vary with age, we expressed them as the SD score (z-score) for age-appropriate normal ranges [15] . In some reports the serum phosphate results were already reported as z-scores. In those that were not, we 
Results
The proband's MPS data revealed a homozygous variant in the SLC34A3 gene, that results in the substitution of alanine to threonine at residue 446, p.(Ala447Thr). This gene was covered 100% in the proband and no other variant of interest was detected. Both parents were heterozygous for this SLC34A3 variant ( Figure 3 ). This variant, SLC34A3(NM_080877.2): c. 1339G>A p.
Ala447Thr, has been reported with a very low allele frequency (3 out of 246, 256 alleles) in the Genome Aggregation Database (gnomAD) database. In silico analysis of this variant via PolyPhen2, MutationTaster, FATHMM, Provean and SIFT all predict it to be likely pathogenic.
The 447 alanine residue lies between the 5 th and 6 th transmembrane domains of the NaPi2c transporter and is highly conserved across mammals with the exception of marsupials, in which is replaced by a serine.
We identified from the literature 29 patients from 21 families who carried compound heterozygous SLC34A3 mutations, and 27 patients from 13 families who carried homozygous mutations, including the patient described here ( Supplementary Table 1 ). Thirteen (45%) of those carrying compound heterozygous mutations were reported to have had rickets; the remainder presented with nephrocalcinosis and/or renal stones. In contrast, 23 of those carrying homozygous mutations were reported to have rickets (85%; p=0.002; χ 2 test). The mean serum phosphate z-score was significantly lower in patients reported to have rickets than those without (-3.3 (SD 1.5) vs -2.1 (1.5); p <0.005). The mean serum phosphate z-score was lower in people with homozygous mutations than those with compound heterozygous mutations: -3.1 (SD 1.5) vs -2.4 (1.6), though this difference was not statistically significant (p=0.12).
Discussion
The young man described here had severe untreated rickets as a result of HHRH. He displayed the classical physical and signs of rickets to a degree that is rarely seen nowadays ( Figure 1A) .
The radiographic signs were similarly gross with Looser zones, fractures, cortical thinning and metaphyseal widening. Looser zones are stress fractures that are a late manifestation of osteomalacia . They are usually multiple and often symmetric, and occur in both weight-bearing bones (pubic rami, medial aspects of the femur and tibia, and metatarsal bones) and non-weight bearing bones (ribs, and lateral border of the scapula).
The primary defect in HHRH is the loss of excessive amounts of phosphate in the urine because of hypofunction of the important renal tubular phosphate transporter, NaPi2c. Chronic hypophosphatemia is responsible for osteomalacia and rickets. Hypophosphatemia also increases the renal 1α-hydroxylation of calcidiol, so calcitriol levels are characteristically increased. This results in increased intestinal calcium absorption, that in turn that causes hypercalciuria, with its renal consequences of nephrocalcinosis and stones [5] . This mechanism is in contrast to that seen in FGF23-mediated hypophosphatemic osteomalacia/rickets, in which calcitriol production is suppressed, so nephrocalcinosis and renal stones are uncommon [19] .
HHRH is caused by homozygous or compound heterozygous mutations in SLC34A3. People carrying a single disease-associated heterozygous mutation also have a phenotype of hypophosphatemia and hypercalciuria, often with renal stones and nephrocalcinosis, but not bone disease [2, 15] . The milder phenotype of heterozygous mutation carriers is likely related to their lesser degree of urine phosphate loss and higher plasma phosphate levels [15] . In people carrying biallelic mutations in SLC34A3 (homozygous or compound heterozygous) there is a substantial variation in the skeletal phenotype, with some patients having severe rickets, some mild and some no skeletal abnormalities [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Our analysis of the published data shows that patients with rickets have significantly lower plasma phosphate than those with only a renal phenotype, and that rickets is more prevalent in those with homozygous mutations than in those with compound heterozygous mutations. The latter effect may also be mediated at least in part by more marked hypophosphatemia in homozygous patients.
Nutritional rickets associated with vitamin D deficiency is common, particularly in the subcontinent , whereas genetic causes are rare, so it is not surprising that, as in our case and others [7, 8, 11] , inappropriate therapy with calciferol and calcium was prescribed.
Failure to heal rickets with such treatment should prompt consideration of alternative diagnoses, as accurate diagnosis is important in selecting the correct therapy. In the case of HHRH, treatment with calcium and vitamin D may be harmful as it can worsen hypercalciuria. HHRH is best treated by oral phosphate salts alone; 1-2.5 g of elemental phosphorus per day in 4-5 divided doses (20-50 mg/kg of elemental phosphorus/day). When our patient was treated with phosphate there was marked symptomatic, biochemical and radiographic improvement, though he will need surgery to correct the severe deformities.
Accurate diagnosis is not only important for treatment, but also for genetic counseling. The number of genetic causes of osteomalacia/rickets that have been identified has increased substantially in recent years . The most frequently encountered are due to mutations in PHEX, DMP1, ENPP1, FGF23 or CLCN5 all of which were included in our gene panel. Rarer causes include somatic mutations in GNAS1, HRAS and NRAS and (in one patient) a translocation close to the α-klotho gene. Biochemical tests can be helpful but some, such as plasma calcitriol can be equivocal. The plasma concentration of calcitriol is typically elevated in HHRH, but was normal in our patient. In their review, Dasgupta et al [15] found that 23% of subjects with HHRH and biallelic SLC34A3 mutations had plasma calcitriol concentrations in the normal range.
Explanations may include day-to-day variability in calcitriol concentrations, or assay difficulties.
Plasma FGF23 levels are typically elevated in all the disorders mentioned above [20] with the exception of HHRH and Dent disease (CLCN5 mutation). In the latter two conditions, FGF23 levels may be low or in the normal range, depending on the type of assay used. Intact FGF23 hormone assays give low readings, but if assays that also detect C-terminal fragments of the hormone are used (as in our case) results in the normal range may be found [4] . Nephrocalcinosis is characteristic of both HHRH and Dent disease, but not the FGF23-related conditions.
Targeted gene panels are increasingly used in circumstances where there are a number of genetic causes for a particular phenotype. In our case a customized gene panel that covered genes involved in vitamin D metabolism, hypophosphatemia and hypophosphatasia provided a rapid result at much reduced cost compared to that of sequencing all the genes of potential interest.
The mutation identified is rare (approximately 1 in 10 5 in heterozygous form in the ExAc database) and no homozygous individuals have previously been reported.
In people carrying bi-allelic mutations in SLC34A3 there is a substantial variation in the skeletal phenotype: some patients having severe rickets, some mild and some no skeletal abnormalities [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Our analysis of the published data shows that patients with rickets have significantly lower plasma phosphate than those with only a renal phenotype, and that rickets is more prevalent in those with homozygous mutations than in those with compound heterozygous mutations. The latter effect may be mediated at least in part by more marked hypophosphatemia in homozygous patients. Because of its rarity there is insufficient data to determine more detailed phenotype-genotype relationships in HHRH -in particular whether mutations affecting specific regions of the NaPi2c molecule are more damaging than others. In conclusion, we have demonstrated the value of a targeted gene panel in identifying the cause of extremely severe rickets in a 12-yearold boy. The novel homozygous mutation in SCL34A3 we found is predicted to disrupt the function of the NaPi2c transporter. Although we have not undertaken functional studies, it is highly conserved and predicted to be pathogenic. A review of the literature suggests that the severity of the bone disease in HHRH is worse with lower plasma phosphate levels and when there are homozygous mutations.
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Figure 2b
Figure 3
Electropherograms from the proband (top) and his parents (below). Both parents are heterozygous for the G>A missense mutation (orange arrows) and the proband is homozygous for the G>A mutation (purple arrow). 
